查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1732905

心房顫動市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療類型（藥物治療）、非藥物治療、最終用途、地區和競爭細分，2020 年至 2030 年

Atrial Fibrillation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Pharmacological Treatment ), Non-Pharmacological Treatment, By End-use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球心房顫動市場價值為 225.4 億美元，預計到 2030 年將達到 341.8 億美元，預測期內複合年成長率為 7.19%。心房顫動是一種常見的心律不整，其特徵是心律不整且心跳過快，會顯著增加中風、心臟衰竭和其他心血管併發症的風險。全球其發病率的不斷上升可歸因於人口老化、肥胖率上升以及生活方式引起的健康問題等因素。這種情況給醫療保健系統帶來了相當大的臨床和經濟負擔。新冠疫情雖然減少了心臟手術，但也凸顯了遠距醫療和遠端監控等數位醫療方法的重要性，預計這些趨勢將持續下去並支持市場成長。因此，對有效心房顫動管理的需求持續上升，推動了治療和診斷的進步。

市場概覽
預測期 2026-2030
2024年市場規模 225.4億美元
2030年市場規模 341.8億美元
2025-2030 年複合年成長率 7.19%
成長最快的領域 醫院
最大的市場 北美洲

關鍵市場促進因素

人口老化加劇推動全球心房顫動市場

主要市場挑戰

缺乏意識

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球心房顫動市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（藥物治療（抗心律不整藥物）、非藥物治療（導管消融、迷宮手術、電復律）
    • 依最終用途（醫院、專科診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美心房顫動市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲心房顫動市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太心房顫動市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美心房顫動市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲心房顫動市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購
  • 產品開發
  • 最新動態

第 13 章：全球心房顫動市場：SWOT 分析

第 14 章：競爭格局

  • Parexel International Corporation
  • AtriCure Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol- Myers Squibb Corporation
  • Cardio Focus Inc.
  • Sanofi Aventis
  • Biosense Webster Inc.
  • Endoscopic Technologies Inc.
  • Abbott Laboratories
  • Johnsons & Johnson Services, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16271

The Global Atrial Fibrillation Market was valued at USD 22.54 Billion in 2024 and is projected to reach USD 34.18 Billion by 2030, growing at a CAGR of 7.19% during the forecast period. Atrial fibrillation, a prevalent cardiac arrhythmia marked by irregular and often rapid heartbeats, significantly increases the risk of stroke, heart failure, and other cardiovascular complications. Its growing incidence globally is attributed to factors such as the aging population, increasing obesity rates, and lifestyle-induced health issues. This condition poses a considerable clinical and financial burden on healthcare systems. The COVID-19 pandemic, while reducing cardiac surgeries, emphasized the importance of digital healthcare approaches like telemedicine and remote monitoring-trends that are expected to persist and support market growth. As a result, the demand for effective atrial fibrillation management continues to rise, driving advancements in treatment and diagnosis.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 22.54 Billion
Market Size 2030USD 34.18 Billion
CAGR 2025-20307.19%
Fastest Growing SegmentHospital
Largest MarketNorth America

Key Market Drivers

Increasing Aging Population is Driving the Global Atrial Fibrillation Market

The growing global aging population is a major factor fueling the expansion of the atrial fibrillation market. Older individuals are more susceptible to this condition due to age-related health risks such as hypertension, obesity, and diabetes. As the proportion of elderly people rises, so does the prevalence of atrial fibrillation. According to the American Heart Association, the likelihood of developing atrial fibrillation doubles with every decade after age 50. Additionally, the World Health Organization reports that by 2030, one in six people globally will be over 60, with the number expected to reach 2.1 billion by 2050. This demographic trend is significantly influencing the demand for atrial fibrillation therapies and solutions.

Key Market Challenges

Lack of awareness

A major hurdle in combating atrial fibrillation globally is the widespread lack of awareness. Despite being common, the condition often goes undiagnosed or is insufficiently treated. This is largely due to limited public understanding of its symptoms and potential severity, resulting in delayed diagnoses and inadequate interventions. The insufficient awareness among both patients and healthcare providers continues to impede efforts to effectively manage and reduce the burden of atrial fibrillation worldwide.

Key Market Trends

Technological Advancements

Technological innovations are transforming the diagnosis and management of atrial fibrillation, leading to improved patient outcomes and more efficient healthcare delivery. As the most common form of cardiac arrhythmia, atrial fibrillation can result in serious complications, making early and accurate detection critical. Advanced tools and procedures, including minimally invasive surgical techniques and remote monitoring solutions, are gaining prominence. These developments cater to growing demand for safer, more precise treatment methods and are playing a pivotal role in expanding the global atrial fibrillation market.

Key Market Players

  • Parexel International Corporation
  • AtriCure Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol- Myers Squibb Corporation
  • Cardio Focus Inc.
  • Sanofi Aventis
  • Biosense Webster Inc.
  • Endoscopic Technologies Inc.
  • Abbott Laboratories
  • Johnsons & Johnson Services, Inc.

Report Scope:

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type:

  • Pharmacological Treatment
  • Non-Pharmacological Treatment

Atrial Fibrillation Market, By End Use:

  • Hospital
  • Specialty Clinics
  • Others

Atrial Fibrillation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion)
    • 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End-Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Atrial Fibrillation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End-Use
    • 6.3.2. Canada Atrial Fibrillation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End-Use
    • 6.3.3. Mexico Atrial Fibrillation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End-Use

7. Europe Atrial Fibrillation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End-Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Atrial Fibrillation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End-Use
    • 7.3.2. United Kingdom Atrial Fibrillation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End-Use
    • 7.3.3. Italy Atrial Fibrillation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End-Use
    • 7.3.4. France Atrial Fibrillation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End-Use
    • 7.3.5. Spain Atrial Fibrillation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End-Use

8. Asia-Pacific Atrial Fibrillation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End-Use
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Atrial Fibrillation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End-Use
    • 8.3.2. India Atrial Fibrillation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End-Use
    • 8.3.3. Japan Atrial Fibrillation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End-Use
    • 8.3.4. South Korea Atrial Fibrillation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End-Use
    • 8.3.5. Australia Atrial Fibrillation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End-Use

9. South America Atrial Fibrillation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End-Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Atrial Fibrillation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End-Use
    • 9.3.2. Argentina Atrial Fibrillation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End-Use
    • 9.3.3. Colombia Atrial Fibrillation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End-Use

10. Middle East and Africa Atrial Fibrillation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End-Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Atrial Fibrillation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End-Use
    • 10.3.2. Saudi Arabia Atrial Fibrillation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End-Use
    • 10.3.3. UAE Atrial Fibrillation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Parexel International Corporation
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. AtriCure Inc.
  • 14.3. Boehringer Ingelheim GmbH
  • 14.4. Boston Scientific Corporation
  • 14.5. Bristol- Myers Squibb Corporation
  • 14.6. Cardio Focus Inc.
  • 14.7. Sanofi Aventis
  • 14.8. Biosense Webster Inc.
  • 14.9. Endoscopic Technologies Inc.
  • 14.10. Abbott Laboratories
  • 14.11. Johnsons & Johnson Services, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer